MetaVia Inc. increased its at-the-market equity program to allow for the sale of up to $4 million in common stock. The clinical-stage biotechnology company filed the prospectus supplement to upsize the offering on July 2, 2026. Ladenburg Thalmann & Co. Inc. is managing the program as the sales agent.
This move amends a November 2025 agreement that previously capped sales at $2.3 million. MetaVia has already raised approximately $2.13 million under those original terms.
The expanded program provides a flexible method for the company to secure additional capital. With a current market capitalization of roughly $7.5 million, the offering represents a substantial potential infusion of funds.